{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-26-039992","form_type":"8-K","ticker":"NMTC","cik":"0001500198","company_name":"NEUROONE MEDICAL TECHNOLOGIES Corp","filed_at":"2026-04-03T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.373844+00:00","generated_at":"2026-05-15T07:35:38.721839+00:00","sec_items":["5.02","5.07","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"NeuroOne shareholders approve reverse stock split and 1.5M share increase in equity plan","bullets":["Shareholders approved reverse stock split at ratio of 1-for-2 to 1-for-15; board to determine final ratio.","Shareholders approved amendment to 2025 Equity Incentive Plan, increasing shares by 1,500,000 and adding 5% annual evergreen increase starting 2027.","Elected Jeffrey Mathiesen and Edward Andrle as Class III directors for three-year terms.","Ratified Baker Tilly US, LLP as independent auditor for fiscal year ending September 30, 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-26-039992","json":"https://secwatch.observer/filing/0001213900-26-039992.json","markdown":"https://secwatch.observer/filing/0001213900-26-039992.md","text":"https://secwatch.observer/filing/0001213900-26-039992.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1500198/000121390026039992/0001213900-26-039992-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1500198/000121390026039992/ea0285085-8k_neuroone.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T07:35:38.721839+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}